JP4494205B2 - カルシウム受容体調節化合物およびその用途 - Google Patents

カルシウム受容体調節化合物およびその用途 Download PDF

Info

Publication number
JP4494205B2
JP4494205B2 JP2004529835A JP2004529835A JP4494205B2 JP 4494205 B2 JP4494205 B2 JP 4494205B2 JP 2004529835 A JP2004529835 A JP 2004529835A JP 2004529835 A JP2004529835 A JP 2004529835A JP 4494205 B2 JP4494205 B2 JP 4494205B2
Authority
JP
Japan
Prior art keywords
group
optionally substituted
alkyl
salt
hydrocarbon group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004529835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510582A (ja
JP2006510582A5 (cg-RX-API-DMAC7.html
Inventor
常雄 安間
亮 森
雅弘 川瀬
宏之 木村
雅都 吉田
アルバート・チャールズ・ジョーコス
スコット・アラン・プラット
クリストファー・ピーター・コレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2006510582A publication Critical patent/JP2006510582A/ja
Publication of JP2006510582A5 publication Critical patent/JP2006510582A5/ja
Application granted granted Critical
Publication of JP4494205B2 publication Critical patent/JP4494205B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2004529835A 2002-08-26 2003-08-21 カルシウム受容体調節化合物およびその用途 Expired - Lifetime JP4494205B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40601202P 2002-08-26 2002-08-26
US46612903P 2003-04-28 2003-04-28
PCT/US2003/026317 WO2004017908A2 (en) 2002-08-26 2003-08-21 Calcium receptor modulating compound and use thereof

Publications (3)

Publication Number Publication Date
JP2006510582A JP2006510582A (ja) 2006-03-30
JP2006510582A5 JP2006510582A5 (cg-RX-API-DMAC7.html) 2008-09-04
JP4494205B2 true JP4494205B2 (ja) 2010-06-30

Family

ID=31949909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004529835A Expired - Lifetime JP4494205B2 (ja) 2002-08-26 2003-08-21 カルシウム受容体調節化合物およびその用途

Country Status (12)

Country Link
US (3) US7514441B2 (cg-RX-API-DMAC7.html)
EP (1) EP1572113B1 (cg-RX-API-DMAC7.html)
JP (1) JP4494205B2 (cg-RX-API-DMAC7.html)
KR (1) KR101050700B1 (cg-RX-API-DMAC7.html)
AU (1) AU2003265585B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0313880B8 (cg-RX-API-DMAC7.html)
CA (1) CA2494700C (cg-RX-API-DMAC7.html)
ES (1) ES2635838T3 (cg-RX-API-DMAC7.html)
NO (1) NO332991B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ538223A (cg-RX-API-DMAC7.html)
PL (1) PL382706A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004017908A2 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL382706A1 (pl) * 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP1992348A4 (en) * 2006-03-08 2009-09-23 Takeda Pharmaceutical PHARMACEUTICAL COMBINATION
WO2007124465A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Stable emulsion formulations
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
ES2499015T3 (es) * 2007-05-08 2014-09-26 Ajinomoto Co., Inc. Agente profiláctico o terapéutico para la diarrea
ES2423932T3 (es) 2007-08-27 2013-09-25 Basf Se Compuestos de pirazol para controlar plagas de invertebrados
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
CA2726610C (en) 2008-06-05 2015-05-05 Asahi Kasei Pharma Corporation Sulfonamide compounds and use thereof
KR20110010781A (ko) * 2008-06-16 2011-02-07 에프. 호프만-라 로슈 아게 Ｎｋ2 수용체 길항제로서의 피롤리딘 유도체
ES2710701T3 (es) 2008-09-24 2019-04-26 Basf Se Compuestos de pirazol para el control de plagas de invertebrados
TWI607996B (zh) 2008-09-24 2017-12-11 巴地斯顏料化工廠 控制無脊椎害蟲之吡唑化合物
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
ES2472918T3 (es) 2009-07-06 2014-07-03 Basf Se Compuestos de piridazina para controlar plagas de invertebrados
ES2461618T3 (es) 2009-07-06 2014-05-20 Basf Se Compuestos de piridacina para el control de plagas de invertebrados
JP2013500246A (ja) 2009-07-24 2013-01-07 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピリジン誘導体化合物
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
JP2014511894A (ja) * 2011-04-20 2014-05-19 グラクソ グループ リミテッド 抗結核化合物としてのテトラヒドロピラゾロ［１，５‐ａ］ピリミジン
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
EP2920181B1 (en) 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds
RU2015143517A (ru) 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
PL2989106T3 (pl) 2013-04-25 2017-08-31 Beigene, Ltd. Połączone związki heterocykliczne jako inhibitory kinazy białkowej
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
EP3129376B1 (en) 2014-03-27 2018-12-26 Janssen Pharmaceutica NV Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors
US10342795B2 (en) 2014-03-27 2019-07-09 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
CA3002144C (en) 2015-10-16 2024-01-23 Eisai R&D Management Co., Ltd. Ep4 antagonists
WO2017110881A1 (ja) * 2015-12-25 2017-06-29 武田薬品工業株式会社 医薬
US11033550B2 (en) * 2016-03-28 2021-06-15 Takeda Pharmaceutical Company Limited Medicament
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
IL293319B1 (en) 2016-08-16 2026-01-01 Beone Medicines Ltd Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
UA125852C2 (uk) 2016-08-31 2022-06-22 Ле Лаборатуар Сервьє Інгібітори клітинних метаболічних процесів
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
WO2018199235A1 (ja) * 2017-04-27 2018-11-01 武田薬品工業株式会社 複素環化合物
AU2018257332B2 (en) * 2017-04-27 2021-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
CN119613408A (zh) 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
MX2020003451A (es) 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
CN113302193B (zh) 2019-01-11 2026-05-29 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
EP3981399A4 (en) 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918074A (en) * 1984-03-12 1990-04-17 Yoshitomi Pharmaceutical Industries, Ltd. Polyazaheterocycle compounds
EP0217142A3 (en) * 1985-09-30 1988-01-07 Yoshitomi Pharmaceutical Industries, Ltd. A polyazaheterocyclic compound
US4746656A (en) 1986-07-21 1988-05-24 E. R. Squibb & Sons, Inc. 1,2,4,7-tetrahydro-2-oxopyrazolo[1,5-a]pyrimidine derivatives
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
ATE267830T1 (de) 1999-08-27 2004-06-15 Abbott Lab Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
ATE363471T1 (de) 2000-01-24 2007-06-15 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
PT1368355E (pt) * 2001-03-14 2006-09-29 Gruenenthal Gmbh Pirazolopirimidinas e tiazolopirimidinas substituidas, como analgesicos
PL382706A1 (pl) * 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie

Also Published As

Publication number Publication date
BRPI0313880B1 (pt) 2016-09-27
NO332991B1 (no) 2013-02-11
NZ538223A (en) 2008-03-28
BRPI0313880B8 (pt) 2021-05-25
EP1572113A2 (en) 2005-09-14
WO2004017908A2 (en) 2004-03-04
NO20051328L (no) 2005-03-15
JP2006510582A (ja) 2006-03-30
KR20050038641A (ko) 2005-04-27
BR0313880A (pt) 2007-11-06
KR101050700B1 (ko) 2011-07-20
AU2003265585B2 (en) 2008-07-03
CA2494700A1 (en) 2004-03-04
US7514441B2 (en) 2009-04-07
CA2494700C (en) 2011-06-28
US20060079536A1 (en) 2006-04-13
AU2003265585A1 (en) 2004-03-11
WO2004017908A3 (en) 2006-01-05
ES2635838T3 (es) 2017-10-05
EP1572113B1 (en) 2017-05-17
US20140155416A1 (en) 2014-06-05
PL382706A1 (pl) 2007-11-26
US20090215746A1 (en) 2009-08-27
EP1572113A4 (en) 2006-11-22
US9447100B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
KR101050700B1 (ko) 칼슘 수용체 조절 화합물 및 이의 용도
JP6359546B2 (ja) Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体
RU2684641C1 (ru) Производные пиразолопиридина в качестве модуляторов активности tnf
CN110267962B (zh) Magl抑制剂
CN105102448B (zh) 作为rock1和rock2抑制剂的苯基吡唑衍生物
WO2003057696A1 (en) Deazapurines and uses thereof
SG192248A1 (en) Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
WO2007005887A2 (en) Androgen receptor modulator compounds, compositions and uses thereof
CA3056355A1 (en) Heterocyclic derivatives for the treatment of cystic fibrosis
AU2021219097A1 (en) P2X3 modulators
JP5199079B2 (ja) アンドロゲン受容体モジュレーター化合物および方法
WO2002004459A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
JP5159630B2 (ja) 縮環複素環誘導体
JP2005239611A (ja) ピラゾロピリミジン誘導体およびその用途
WO2022049253A1 (en) Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
SK10712002A3 (sk) Tienopyridínové zlúčeniny, farmaceutický prostriedok, ktorý ich obsahuje, ich použitie a spôsob ich výroby
KR20000010617A (ko) 티에노피리딘 유도체 및 이의 용도
JP6770962B2 (ja) チアゾール誘導体の製造方法
CN118382623A (zh) 用于治疗疾病或障碍的萘啶酮衍生物
TWI925049B (zh) 含有ａｂｈｄ６拮抗劑之醫藥組合物、ａｂｈｄ６相關疾病之治療及/或預防劑、及用途
JP2002255971A (ja) 縮合複素環誘導体、その製造法および用途
JP2026507091A (ja) アリール基三環式ｓｔｉｎｇ作動薬及びその使用
JP2013053070A (ja) ジヒドロピロロキノリン誘導体
EA047826B1 (ru) Ингибиторы magl на основе пиразола

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100316

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100407

R150 Certificate of patent or registration of utility model

Ref document number: 4494205

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130416

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130416

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130416

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140416

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term